Research Analysts’ Weekly Ratings Changes for Evolent Health (EVH)

A number of research firms have changed their ratings and price targets for Evolent Health (NYSE: EVH):

• 11/22/2024 – Evolent Health had its price target lowered by analysts at JPMorgan Chase & Co. from $45.00 to $15.00. They now have an “overweight” rating on the stock.
• 11/18/2024 – Evolent Health had its price target lowered by analysts at Oppenheimer Holdings Inc. from $34.00 to $28.00. They now have an “outperform” rating on the stock.
• 11/13/2024 – Evolent Health had its price target lowered by analysts at Citigroup Inc. from $33.00 to $21.00. They now have a “buy” rating on the stock.
• 11/12/2024 – Evolent Health had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $20.00 price target on the stock.
• 11/11/2024 – Evolent Health had its price target lowered by analysts at Barclays PLC from $39.00 to $19.00. They now have an “overweight” rating on the stock.
• 11/8/2024 – Evolent Health had its price target lowered by analysts at Oppenheimer Holdings Inc. from $45.00 to $34.00. They now have an “outperform” rating on the stock.
• 11/8/2024 – Evolent Health was downgraded by analysts at Stephens from an “overweight” rating to an “equal weight” rating. They now have a $16.00 price target on the stock, down previously from $38.00.
• 10/29/2024 – Evolent Health had its price target lowered by analysts at Citigroup Inc. from $35.00 to $33.00. They now have a “buy” rating on the stock.
• 10/11/2024 – Evolent Health is now covered by analysts at KeyCorp. They set an “overweight” rating and a $35.00 price target on the stock.
• 10/10/2024 – Evolent Health was upgraded by analysts at KeyCorp to a “strong-buy” rating.
• 10/8/2024 – Evolent Health had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.

Evolent Health Trading Down 2.9 %

EVH opened at $11.25 on Monday. Evolent Health, Inc. has a fifty-two week low of $11.17 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -12.36 and a beta of 1.58. The company’s 50 day moving average price is $23.26 and its two-hundred day moving average price is $23.74.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Brophy Wealth Management LLC purchased a new stake in Evolent Health during the third quarter worth about $405,000. Barclays PLC increased its position in Evolent Health by 181.3% during the 3rd quarter. Barclays PLC now owns 273,776 shares of the technology company’s stock valued at $7,742,000 after purchasing an additional 176,445 shares during the period. Wellington Management Group LLP increased its position in Evolent Health by 12.8% during the 3rd quarter. Wellington Management Group LLP now owns 12,595,459 shares of the technology company’s stock valued at $356,200,000 after purchasing an additional 1,426,747 shares during the period. State Street Corp boosted its holdings in shares of Evolent Health by 1.0% during the 3rd quarter. State Street Corp now owns 2,725,375 shares of the technology company’s stock valued at $77,074,000 after buying an additional 25,967 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Evolent Health by 1,948.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after purchasing an additional 1,422,385 shares in the last quarter.

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.